Transcriptional down-regulation of IGFBP-3 in human hepatocellular carcinoma cells is mediated by the binding of TIA-1 to its AT-rich element in the 3'-untranslated region

Cancer Letters

Volumn 297, Issue 2, 2010, Pages 259-268

  Subramaniam, Kothandharaman ^a   Ooi, London Lucien P J ^b   Hui, Kam M ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

AU rich elements; Human hepatocellular carcinoma; IGFBP 3; TIA 1; Transcriptional regulation

Indexed keywords

EUKARYOTIC TRANSLATION FACTOR 1; EUKARYOTIC TRANSLATION FACTOR 3; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; MEMBRANE PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; T CELL RESTRICTED INTRACELLULAR ANTIGEN 1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; POLYADENYLIC ACID BINDING PROTEIN; TIA1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BINDING AFFINITY; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; AT RICH SEQUENCE; BINDING SITE; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; AT RICH SEQUENCE; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LIVER NEOPLASMS; POLY(A)-BINDING PROTEINS; PROMOTER REGIONS, GENETIC; TRANSFECTION;

EID: 77956417737     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.019     Document Type: Article

References (37)

1. Maniatis T., Reed R. An extensive network of coupling among gene expression machines. Nature 2002, 416:499-506.
2. Orphanides G., Reinberg D. A unified theory of gene expression. Cell 2002, 108:439-451.
3. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
4. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
5. Osborne H.B. An insight into the post-transcriptional control of gene expression in cell function. Biol. Cell. 2003, 95:125-127.
6. Keene J.D., Lager P.J. Post-transcriptional operons and regulons co-ordinating gene expression. Chromosome Res. 2005, 13:327-337.
7. Anderson P., Jackson R.J., Wickens M. Life and death in the cytoplasm: messages from the 3' end. Curr. Opin. Genet. Dev. 1997, 7:220-232.
8. Goodwin E.B., Kuertsen S. The power of the 3' UTR: translational control and development. Nat. Rev. Genet. 2003, 4:626-637.
9. Bohjane P.R., June C.H., Lindsten T., Petryniak B., Thompson C.B. An inducible cytoplasmic factor (AU-B) binds selectively to AUUUA multimers in the 3' untranslated region of lymphokine mRNA. Mol. Cell. Biol. 1991, 11:3288-3295.
10. Balmer L.A., Beveridge D.J., Jazayeri J.A., Leedman P.J., Thomson A.M., Walker C.E. Identification of a novel AU-rich element in the 3' untranslated region of epidermal growth factor receptor mRNA that is the target for regulated RNA-binding proteins. Mol. Cell. Biol. 2001, 21:2070-2084.
11. Belasco J.G., Greenberg M.E., Zubiaga A.M. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol. Cell. Biol. 1995, 15:2219-2230.
12. Blackshear P.J., Carrick D.M., Lai W.S. Influence of nonameric AU-rich tristetraprolin-binding sites on mRNA deadenylation and turnover. J. Biol. Chem. 2005, 280:34365-34377.
13. Audic Y., Hartley R.S. Post-transcriptional regulation in cancer. Biol. Cell. 2004, 96:479-498.
14. Esteller M., López de Silanes I., Quesada M.P. Aberrant regulation of messenger RNA 3'-untranslated region in human cancer. Cell. Oncol. 2007, 29:1-17.
15. Piecyk M., Wax S., Beck A.R., Kedersha N., Gupta M., Maritim B., Chen S., Gueydan C., Kruys V., Streuli M., Anderson P. TIA-1 is a translational silencer that selectively regulates the expression of TNF-α. EMBO J. 2000, 19:4154-4163.
16. Hwa V., Oh Y., Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 1999, 20:761-787.
17. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat. Rev. Cancer 2008, 8:915-928.
18. Baxter R.C., Firth S.M. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 2002, 23:824-854.
19. Dombrowski F., Ramadori G., Scharf J.G. The IGF axis and hepatocarcinogenesis. Mol. Pathol. 2001, 54:138-144.
20. Aishima S., Basaki Y., Fotovati A., Hosoi F., Kuroda Y., Maehara Y., Maruyama Y., Nishihara Y., Oda Y., Oie S., Taguchi K., Taketomi A. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci. 2006, 97:1182-1190.
21. Fujikawa T., Hanafusa T., Matsumoto E., Nakatsukasa H., Nouso K., Onishi T., Suzuki M., Takuma Y., Tanaka H., Uemura M., Yumoto E., Yumoto Y. IGFBP-3 expression in hepatocellular carcinoma involves abnormalities in TGF-beta and/or Rb signaling pathways. Int. J. Oncol. 2005, 27:1223-1230.
22. Deng W.X., Luo J.W., Luo S.M., Tan W.M., Zhuang S.M. Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World J. Gastroenterol. 2005, 11:4272-4276.
23. Capuano G., Colao A., D'Agostino L., Manguso F., Mattera D., Pivonello R., Puzziello A. Increased IGF-I: IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin. Endocrinol. (Oxf.) 2003, 59:699-706.
24. Gao H., Ooi L.L., Pasupathy S., Tan P.H., Wu X., Hui K.M. Systemic administration of naked DNA with targeting specificity to mammalian kidneys. Gene Ther. 2005, 12:477-486.
25. Tan M.G., Aw S.E., Ooi L.L., Hui K.M. Cloning and identification of hepatocellular carcinoma down-regulated mitochondrial carrier protein, a novel liver-specific uncoupling protein. J. Biol. Chem. 2004, 279:45235-45244.
26. Wang S.M., Ooi L.L., Hui K.M. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin. Cancer Res. 2007, 13:6275-6283.
27. Soong T.W., Hui K.M. Locus-specific transcriptional control of HLA genes. J. Immunol. 1992, 149:2008-2020.
28. Brazas R., Garcia-Blanco M.A., Lasda E., Niranjanakumari S. Reversible cross-linking combined with immunoprecipitation to study RNA-protein interactions in vivo. Methods 2002, 26:182-190.
29. Grisham J.W., Lee J.S., Thorgeirsson S.S. Functional genomics of hepatocellular carcinoma. Hepatology 2006, 43(Suppl. 1):S145-S150.
30. DePinho R.A., Farazi P.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
31. Alexia C., Fallot G., Groyer A., Lasfer M., Schweizer-Groyer G. An evaluation of the role of insulin-like growth factors (IGF) and of type-1 IGF receptor signaling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem. Pharmacol. 2004, 68:1003-1015.
32. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
33. Chen K., Joseph K., Raymond J.R., Subramaniam K., Tholanikunnel B.G. The 3'-untranslated region of the beta2-adrenergic receptor mRNA regulates receptor synthesis. J. Biol. Chem. 2004, 279:27108-27115.
34. Fujikawa T., Hanafusa T., Higashi T., Nakamura S., Nakatsukasa H., Nouso K., Onishi T., Takuma Y., Taniyama M., Uemura M., Yumoto E., Yumoto Y. Reduced expression of insulin-like factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 2002, 176:149-158.
35. Anderson P., Beck A.R., Chen S., Gueydan C., Gupta M., Kedersha N., Kruys V., Maritim B., Piecyk M., Streuli M., Wax S. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J. 2000, 19:4154-4163.
36. Anderson P., Balch G.C., Beauchamp R.D., Dixon D.A., Kedersha N., Prescott S.M., Zimmerman G.A. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J. Exp. Med. 2003, 198:475-481.
37. Anderson P. Post-transcriptional control of cytokine production. Nat. Immunol. 2008, 9:353-359.